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Generation of soluble cytokine receptors is a general phenomenon, and the roles of several such receptors 
have been investigated in clinical settings. Unlike other soluble cytokine receptors, soluble interleukin-6 
receptor (sIL-6R) can act as an agonist and thus is implicated as an important modulator in the 
acute-phase reaction of prolonged inflammation. The purpose of the present study was to determine the 
roles of pleural sIL-6R in both differential diagnosis of pleural diseases and in the induction of acute-phase 
protein. Specific sandwich enzyme-linked immunosorbent assays were used to determine sIL-6R and IL-6 in 
19 tuberculous, 48 malignant and 10 transudative effusions. Although IL-6 levels in pleural effusions were 
strikingly different, no significant differences in pleural sIL-6R levels were found between the groups. 
Pleural levels of IL-6 were invariably much higher, whereas those of sIL-6R were invariably lower than 
serum levels. Furthermore, IL-6, but not sIL-6R, levels in effusions correlated significantly with serum 
C-reactive protein levels. These results suggest that: (1) pleural levels of sIL-6R are not increased even in 
strong inflammation such as tuberculous pleurisy, nor significantly different among pleural diseases; and (2) 
the local levels of sIL-6R are not as important as expected for the induction of acute-phase proteins in 
patients with pleural diseases. 
Introduction 
Interleukin-6 (IL-6) is a cytokine of 21 kDa with 
multifunctions (1). Its biologic effects are exerted by 
interaction with specific interleukin-6 receptors (IL- 
6R), identified as two different membrane glycopro- 
teins; i.e. an 80-kDa protein (a-chain) as ligand- 
binding receptor, and a 130-kDa protein Q-chain) as 
non-ligand-binding but signal-transducing receptor 
(2,3). The soluble form of human IL-6 a-chain R 
(sIL-6R) was characterized as 53-kDa molecule in 
normal human urine (4). From the clinical point of 
view, there has been no report concerning the clinical 
significance of sIL-6R except one (5) which demon- 
strated the enhanced release of sIL-6R by HIV 
infection. 
Since sIL-6R may act as an important modulator 
for IL-6-mediated immune responses (2,3,5,6), it 
would be interesting to measure its level in pleural 
fluid where the IL-6 level is high. Tuberculous and 
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one-third of malignant effusions have been shown to 
contain marked levels of IL-6 (>500 U ml- ‘) (7). 
Furthermore, not only IL-6 but also sIL-6R may 
have a pivotal role in acute-phase protein induction 
(1,s). Recent studies have indicated that sIL-6R 
might be a critical modulator for the induction of 
such proteins in prolonged inflammation, where IL-6 
levels persistently increased and down-regulated the 
IL-6 binding u-chain receptor (8). In this context, the 
levels of sIL-6R in effusions would contribute to 
production of acute-phase proteins in inflammatory 
pleural diseases. 
This study was planned to prove whether the 
measurement of sIL-6R in pleural effusions is helpful 
for differential diagnosis, and to prove the impor- 
tance of sIL-6R for induction of C-reactive protein 
(CRP), a representative acute-phase protein. 
Materials and Methods 
PATIENTS 
Seventy-seven stocked pleural effusions were used 
for the present study. Of these, 19 were tuberculous, 
48 were malignant and 10 were transudative effu- 
sions. Diagnoses of the tuberculous effusions were 
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made by the detection of Mycobacterium tuberculosis 
in the pleural fluid or findings from the pleural 
biopsied specimens (n = 6), or by extensive exclusion 
of other diseases and a good response to anti- 
tuberculous chemotherapy (n= 13). Diagnosis of 
malignant effusion was made by cytopathological 
detection of malignant cells in the effusion. Transu- 
dative effusions were from cardiac failure or hypo- 
proteinemia. 
Serum samples obtained at the same time of tho- 
racentesis were available in 23 patients with tubercu- 
lous (n=4), malignant (n= 14) or transudative (n=5) 
effusions for study of the serum-pleural fluid 
gradient. The data of serum CRP, determined by a 
turbidimetric immunoassay on the same day as 
thoracentesis, were available in 48 patients with 
tuberculous (n = 13) transudative (n=7), or 
malignant effusions (n = 23). 
MEASUREMENTS OF SOLUBLE RECEPTORS AND 
CYTOKINES 
The sIL-6R was measured according to the method 
by Nakajima et al. (9). Two antibodies, MT-18 
(2pg ml ~ ‘; Tosoh, Kanagawa, Japan) (10) and the 
biotinylated polyclonal antibody (1 lug ml - ‘) were 
used. MT-l 8 (100 ,ug well - ‘) was coated onto plastic 
96-well flat-bottomed plates overnight at 4°C. After 
blocking with 1% bovine serum albumin (Sigma, 
St. Louis, MO, U.S.A.) in Tris-HCl buffered 
saline (TBS; 200 pl), samples or recombinant sIL-6R 
(Tosoh) with 0.1% BSA-TBS (100~1) were incubated 
for 2 h at room temperature, then incubated 
with biotinylated polyclonal anti-sIL-6R guinea pig 
IgG fraction for 2 h. The plates were then incu- 
bated with horseradish-peroxidase-coupled strepta- 
vidin (ZYMED Inc., South San Francisco, CA, 
U.S.A.) for 30 min prior to development with 
o-phenylendiamine substrate. The detection limit of 
the assay was 0.1 ng ml - ‘. Since no influence was 
observed in this assay system on the determination of 
recombinant sIL-6R concentrations by the addition 
of pleural fluids, the possibility was excluded that the 
assay system for sIL-6R might be interfered with 
by a high amount of IL-6 or by something in the 
pleural effusion (data not shown). Interleukin-6 was 
measured by a specific luminescence sandwich-type 
enzyme-linked immunosorbent assay (ELISA), a 
modification of the method described previously (1 l), 
which consisted of two monoclonal anti-human IL-6 
antibodies (IG61, IC67, Toray, Tokyo, Japan) and 
chemiluminescent detection using Lumi-phos 
(Lumigen Inc., Detroit, MI, U.S.A.). The detec- 
tion limit of this assay was 0.5 pg ml - ‘. All 
measurements were carried out in duplicate. 
STATISTICAL ANALYSIS 
Data are expressed as the mean + SD, unless other- 
wise stated. The significance of difference of sIL-6R 
and IL-6 levels in the pleural effusion was evaluated 
with Kruskal-Wallis tests, and additional Mann- 
Whitney U-tests for the significance of differences 
between two groups. The significance of difference of 
IL-6 or sIL-6R between serum and pleural effusion 
was evaluated by a Wilcoxon signed ranks test. The 
correlations between IL-6 and sIL-6R, or these and 
CRP levels were evaluated by using Spearman’s 
signed rank sum test. Statistical significance was 
defined as PcO.05. 
Results 
Each concentration of IL-6 and sIL-6R in pleural 
fluids is shown in Fig. 1. Although the mean 
sIL-6R level in the tuberculous effusion (n= 19, 
60.9 & 30.8 ng ml-‘) was higher than that of 
malignant (n =48; 49.2 * 20.6 ng ml ~ ‘) or transuda- 
tive effusions (n= 10; 43.3 * 20.4 ng ml- ‘) [Fig. l(a)], 
there were no significant differences among 
them. Pleural IL-6 levels were 25 207 + 21 247, 
5397 f. 7427, and 220 * 162 pg ml ~ ‘, in the tubercu- 
lous, malignant and transudative effusions, respect- 
ively [Fig. l(b)]. There were significant differences of 
IL-6 levels between tuberculous and malignant or 
transudative effusions (P<O.Ol), and between 
malignant and transudative effusions (P<O.O5). Since 
high IL-6 levels were observed in both tuberculous 
and malignant effusions, IL-6 levels are of limited 
clinical value in differential diagnosis. 
There was no correlation between the concen- 
trations of IL-6 and sIL-6R (Y,= - 0.03). Comparing 
within each group, there was a weak negative 
correlation in the malignant effusion (rs= - 0.40; 
n=48; P<O.O5), whereas there was no correlation in 
the tuberculous effusion (u,=O.27; n= 19; ns). 
Because the concentration of sIL-6R in pleural 
effusions was found to be unexpectedly low, the 
sIL-6R concentration gradient between pleural 
effusion and serum was determined using 23 paired 
samples. Pleural sIL-6R concentration was invari- 
ably much lower than serum concentration (45.1 f 
23.6 ng ml- ’ vs. 123.2 f 41.5 ng ml- ‘; P<O.OOl). In 
contrast, pleural IL-6 concentration was always 
much higher than that of serum (7065 * 
15 228 pgmll’ vs. 90 & 175 pgml-‘). 
There was a significant correlation between CRP 
and IL-6 levels in pleural effusions (~~~0.68; 
P<O.OOl). However, there was no significant corre- 
lation between CRP and sIL-6R (Y,= - 0.17). The 
same relationships were observed when compared in 
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Fig. 1 Distribution of (a) soluble interleukin-6 receptor 
and (b) interleukin-6 concentrations in the tuberculous (Tb), 
transudative (Tr) and malignant (Malig) effusions. These 
concentrations were determined by ELISA. The bars 
represent geometric means. 
tuberculous effusions alone (R,=O.51, P~0.01 for 
IL-6; v,= - 0.20, ns for sIL-6R). 
Discussion 
The present study demonstrated that pleural 
sIL-6R levels do not differ between tuberculous, 
malignant and transudative effusions, and that the 
pleural concentration of sIL-6R is much less than its 
serum concentration. It was rather surprising that 
local levels of sIL-6R were not increased even in 
strong inflammation such as tuberculous pleurisy. 
However, this might be explained by the fact that 
T-cells have only several hundred IL-6 binding sites 
per cell, regardless of activation (12). 
Stimulation with IL-6 resulted in a rapid down- 
regulation of IL-6 receptor (u-chain) at the cell 
surface in vitro. Responder cells thus lose IL-6 
binding sites and no longer respond to IL-6. This 
refractory state can be overcome by addition of 
sIL-6R (8). In this way, sIL-6R was suggested to have 
an important role in the IL-6 mediated functions in 
usual inflammatory states. If sIL-6R is important, 
sIL-6R concentration would have a correlation 
with CRP, which is induced mainly by IL-6 (13). 
However, this study found that only pleural IL-6 
levels correlated with CRP concentrations, while no 
correlation was observed between CRP and sIL-6R. 
Since sIL-6R is already abundant in serum, which is 
different from the experimental system in vitro, these 
results indicated that the effect of sIL-6R may be 
saturated in the liver, where acute-phase proteins are 
produced. 
In conclusion, sIL-6R production at a local 
inflammation site may be very low. The locally 
produced sIL-6R may work at the local level but not 
be a critically important modulator for systemic 
acute-phase responses in patients with pleural 
diseases. 
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